THE BLOOD FACTOR
-
European Haemophilia Consortium New Products Review
Read the latest research news about innovative coagulation products – factor replacement products, non-factor therapies and gene therapies – in the European Haemophilia Consortium New...
-
Global dosing hold in fitusiran trials initiated by Sanofi Genzyme to investigate new adverse events
A joint statement of the World Federation of Hemophilia (WFH), European Haemophilia Consortium (EHC) and National Hemophilia Foundation (NHF) November 6, 2020 – The WFH,...
-
FDA denies approval of Biomarin’s FVIII gene therapy
In a decision that surprised many, the U.S. Food and Drug Administration (FDA) last week denied approval of Biomarin’s FVIII gene therapy, branded Roctavian. The...
-
Update of Phase 2b trial of UniQure’s AMT-061 gene therapy trial in hemophilia B
Dr. Steven Pipe, Pediatric Medical Director of the Hemophilia and Coagulation Disorders Program in Ann Arbor Michigan, presented an update at the World Federation of...
-
Dangerously high FIX levels reported in hemophilia B gene therapy
Montreal – June 29, 2020 – During the question-and-answer period of a session on gene therapy during the World Federation of Hemophilia’s virtual summit (June...